Neurocrine Biosciences, Inc. (NBIX) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

At any time, please press star zero, and a member of our team will be happy to help you. ¶¶ ¶¶ ? ? ? ? Thank you for your continued patience. Your meeting will begin shortly. ¶¶ Thank you. ¶¶ © transcript Emily Beynon Thank you. Please stand by, your meeting is about to begin. Hello and welcome everyone joining today's Neurocrine Biosciences Q1 2026 earnings call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. To register to ask a question at any time, please press star 1 on your telephone keypad. Please note, this call is being recorded. We are standing by if you should need any assistance. It is now my pleasure to turn the meeting over to Todd Tushla, Vice President of Investor Relations. Please go ahead. Thank you, and happy Cinco de Mayo to everyone. Welcome to Neurocurrent Biosciences' first quarter 2026 earnings call. Joining me today are Kyle Gano, Chief Executive Officer, Matt Abernathy, Chief Financial Officer, Eric Benevich, Chief Commercial Officer, Sanjay Kaswani, Chief Medical Officer, and Samir Sedanti, Vice President of Strategy and Corporate Development. During today's call, we will be making forward-looking statements, including statements containing projections regarding future events, such as the anticipated closing of our acquisition of Celeno Therapeutics. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. In addition, some of the information discussed today includes non-GAAP financial measures that have not been calculated in accordance with U.S. GAAP. Reconciliations of these non-GAAP financial measures ...